Sonam Puri,
MD
Languages Spoken: English, Hindi, Panjabi
Dr Sonam Puri MD. is an Assistant Professor in the Division of Oncology, Department of Medicine at the University of Utah. She is a specialist in medical oncology with a focus on the treatment of thoracic malignancies. She is originally from New Delhi, India and earned her medical degree from Pandit B.D Sharma PGIMS Rohtak, Haryana. She then completed her Internal Medicine Residency at the University of Connecticut Health Center in Farmington, Connecticut and fellowship in Hematology and Oncology at H. Lee Moffitt Cancer Center and Research Institute/ University of South Florida in Tampa, Florida.
Dr Puri’s research interests include clinical research in thoracic malignancies, with emphasis on immunotherapy, targeted therapy and other novel treatment strategies for non-small and small cell lung cancer. She is an active member of the Lung Cancer Disease Center of Excellence at the Huntsman cancer institute. She is also a member of several national and international professional organizations like American Society of Medical Oncology, Southwest Oncology Group, Society of Immunotherapy of Cancer and International association of study of lung cancer where she serves as a member of the membership committee.
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine Educational Commission for Foreign Medical Graduates |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.8/ 5
Care provider's explanation of condition/problem
4.8/ 5
Care provider's effort to include me in decisions
4.9/ 5
Wait time at clinic
4.5/ 5
Care provider's concern for questions & worries
4.9/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
September 06, 2022
HUNTSMAN CANCER CENTER
I am thankful for the help from Dr. Puri.
UofU Patient
August 09, 2022
HUNTSMAN CANCER CENTER
Concerned why chemo was stopped when scheduled. Some is better than none.....
UofU Patient
January 15, 2022
HUNTSMAN CANCER CENTER
I feel the kindness and support from Dr. Puri. I truly appreciate her.
UofU Patient
November 27, 2021
HUNTSMAN CANCER CENTER
Dr. Puri is always so patient and willing to answer my questions. She has become a trusted friend in addition to being my oncologist. I feel like I am getting the best care available.
UofU Patient
November 21, 2021
HUNTSMAN CANCER CENTER
Dr. Puri is a caring, competent and appears to have expertise in oncology
UofU Patient
October 24, 2021
HUNTSMAN CANCER CENTER
Physician was respectful and detailed my condition with care and concern
UofU Patient
September 30, 2021
HUNTSMAN CANCER CENTER
I was told I was going to be involved in a study I went through several procedures EKGs blood draws at goes for the study it wasn't until the day before that I was told I was not going to qualify I feel like this really sent me back in terms of treatment
UofU Patient
September 06, 2021
HUNTSMAN CANCER CENTER
Very poor communication and very uncaring
UofU Patient
September 02, 2021
HUNTSMAN CANCER CENTER
I really like my doctor's at Huntsman's
UofU Patient
August 12, 2021
HUNTSMAN CANCER CENTER
Pleased with Dr Puri
UofU Patient
June 23, 2021
HUNTSMAN CANCER CENTER
normal
UofU Patient
May 30, 2021
HUNTSMAN CANCER CENTER
Dr Puri is great. Just wish the medicine I need was available so i would not have to go to Banner Cancer
UofU Patient
April 18, 2021
HUNTSMAN CANCER CENTER
excellent
UofU Patient
February 26, 2021
HUNTSMAN CANCER CENTER
if anything new comes around about lung cancer, I would like to be informed! Thanks to all the staff for their part in the grand scheme of my cancer!! If you are ever asked to join PEP, the program is invaluable!!!
UofU Patient
February 25, 2021
HUNTSMAN CANCER CENTER
Everyone here is just so wonderful and caring.
UofU Patient
December 19, 2020
HUNTSMAN CANCER CENTER
Dr. Puri explained why we needed to delay getting me on a treatment plan immediately. There were a couple of additional scans that need to be done and we need to obtain the results of the biomarker screening.
Dr Sonam Puri MD. is an Assistant Professor in the Division of Oncology, Department of Medicine at the University of Utah. She is a specialist in medical oncology with a focus on the treatment of thoracic malignancies. She is originally from New Delhi, India and earned her medical degree from Pandit B.D Sharma PGIMS Rohtak, Haryana. She then completed her Internal Medicine Residency at the University of Connecticut Health Center in Farmington, Connecticut and fellowship in Hematology and Oncology at H. Lee Moffitt Cancer Center and Research Institute/ University of South Florida in Tampa, Florida.
Dr Puri’s research interests include clinical research in thoracic malignancies, with emphasis on immunotherapy, targeted therapy and other novel treatment strategies for non-small and small cell lung cancer. She is an active member of the Lung Cancer Disease Center of Excellence at the Huntsman cancer institute. She is also a member of several national and international professional organizations like American Society of Medical Oncology, Southwest Oncology Group, Society of Immunotherapy of Cancer and International association of study of lung cancer where she serves as a member of the membership committee.
Academic Locations
Huntsman Cancer Institute Research North
801-213-4266
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine Educational Commission for Foreign Medical Graduates |
Research Interests
- Small Cell Lung Cancer
- Thoracic Oncology
Education History
| Internship/Residency | University of Connecticut School of Medicine Internal Medicine, Clinical Educator Track Intern/Resident, 2016 |
| Undergraduate | Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences Medicine; Surgery M.D., 2011 |
| Fellowship | University of South Florida, H. Lee Moffitt Cancer Center & Research Institute Hematology and Oncology Fellow, |
Selected Publications - Journal Articles
Journal Article
- Wang X, Kerrigan K, Puri S, Shen J, Akerley W, Haaland B (2022). Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data. Cancers (Basel), 14(3).
- Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Blaquier JB, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Garrido P, Khan H, Baggi A, Mascaux C, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Mtivier AC, Falchero L, Felip E, Genova C, Mazieres J, Tapan U, Brahmer J, Bria E, Puri S, Popat S, Reckamp KL, Morgillo F, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Avrillon V, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Barlesi F, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V, TERAVOLT study group (2022). A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry. J Thorac Oncol.
- Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, Patel S (2022). A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern. JTO Clin Res Rep, 3(3), 100280.
- Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, Khan H, Mamdani H, Nagasaka M, Puri S, Liu SV, Korn WM, Nieva JJ (2021). Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget, 12(25), 2449-2458.
- Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, DAmico TA, DAvella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M (2021). Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(12), 1441-1464.
- Ireland AS, Micinski AM, Kastner DW, Guo B, Wait SJ, Spainhower KB, Conley CC, Chen OS, Guthrie MR, Soltero D, Qiao Y, Huang X, Tarapcsk S, Devarakonda S, Chalishazar MD, Gertz J, Moser JC, Marth G, Puri S, Witt BL, Spike BT, Oliver TG (2020). MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. Cancer Cell, 38(1), 60-78.e12.
- Puri S, Saltos A, Perez B, Le X, Gray JE (2020). Locally Advanced, Unresectable Non-Small Cell Lung Cancer. Curr Oncol Rep, 22(4), 31.
Review
- Higgins KA, Puri S, Gray JE (2022). Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer. [Review]. J Clin Oncol, 40(6), 576-585.
- Kerrigan K, Puri S (2022). Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer. [Review]. Curr Oncol Rep, 24(1), 113-123.
- Naqash AR, Kihn-Alarcn AJ, Stavraka C, Kerrigan K, Maleki Vareki S, Pinato DJ, Puri S (2020). The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer. [Review]. Ann Transl Med, 9(12), 1034.
- Florou V, Puri S, Garrido-Laguna I, Wilky BA (2020). Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. [Review]. Ann Transl Med, 9(12), 1035.
- Bindal P, Gray JE, Boyle TA, Florou V, Puri S (2020). Biomarkers of therapeutic response with immune checkpoint inhibitors. [Review]. Ann Transl Med, 9(12), 1040.
- Puri S, Shafique M (2020). Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. [Review]. Drugs Context, 9.
Editorial
Other
- Nagasaka M, Asad MFB, Al Hallak MN, Uddin MH, Sukari A, Baca Y, Xiu J, Magee D, Mamdani H, Uprety D, Kim C, Xia B, Liu SV, Nieva JJ, Lopes G, Bepler G, Borghaei H, Demeure MJ, Raez LE, Ma PC, Puri S, Korn WM, Azmi AS (2021). Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). Lung Cancer (160, pp. 92-98). Ireland.
- Kerrigan K, Wang X, Haaland B, Adamson B, Patel S, Puri S, Akerley W (2021). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status. Clin Lung Cancer (22(4), pp. 260-267.e2). United States.
Global Impact
Education History
| Undergraduate | Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences Medicine; Surgery M.D. |